HOOKIPA Pharma To Report Second Quarter 2020 Financial Results on August 13, 2020
04 August 2020 - 9:00PM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that it will release financial results for the second
quarter ended June 30, 2020 before the market opens on Thursday,
August 13, 2020.
The Company will not be conducting a conference
call in conjunction with this earnings release. Until otherwise
noted, the Company will only conduct an earnings conference call in
conjunction with its fourth quarter earnings releases.
About
HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics targeting infectious diseases and cancers based
on its proprietary arenavirus platform that reprograms the body’s
immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, non-replicating (VaxWave®) and replicating (TheraT®),
induce robust antigen-specific CD8+ T cells and
pathogen-neutralizing antibodies. HOOKIPA’s “off-the-shelf” viral
vectors target antigen presenting cells in vivo to activate the
immune system. Both technologies enable repeat administration to
augment and refresh immune responses. As a monotherapy, our
replicating arenavirus technology has the potential to induce CD8+
T cell response levels previously not achieved by other
immuno-therapy approaches.
HOOKIPA’s non-replicating prophylactic
Cytomegalovirus (CMV) vaccine candidate is currently in a Phase 2
clinical trial for patients awaiting kidney transplantation. To
expand its infectious disease portfolio, HOOKIPA entered into a
collaboration and licensing agreement with Gilead Sciences, Inc. to
research arenavirus-based functional cures for HIV and chronic
Hepatitis B infections.
In addition, HOOKIPA is building a proprietary
immuno-oncology pipeline by targeting virally mediated cancer
antigens, self-antigens and next-generation antigens. The lead
replicating arenavirus oncology product candidates, HB-201 and
HB-202, are in development for the treatment of Human Papilloma
Virus 16-positive cancers. The Phase 1/2 clinical trial for HB-201
was initiated in December 2019. The HB-202 IND application was
cleared by the FDA in June 2020.
Find out more about HOOKIPA online at
www.hookipapharma.com.
HOOKIPA Forward Looking
Statements
Certain statements set forth in this press
release constitute “forward-looking” statements within the meaning
of the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements can be identified by terms such
as “believes,” “expects,” “plans,” “potential,” “would” or similar
expressions and the negative of those terms. Such forward-looking
statements involve substantial risks and uncertainties that could
cause HOOKIPA’s research and clinical development programs, future
results, performance or achievements to differ significantly from
those expressed or implied by the forward-looking statements. Such
risks and uncertainties include, among others, the uncertainties
inherent in the drug development process, including HOOKIPA’s
programs’ early stage of development, the process of designing and
conducting preclinical and clinical trials, the regulatory approval
processes, the timing of regulatory filings, the challenges
associated with manufacturing drug products, HOOKIPA’s ability to
successfully establish, protect and defend its intellectual
property, risks relating to business interruptions resulting from
the coronavirus (COVID-19) disease outbreak or similar public
health crises, the impact of COVID-19 on the enrollment of patients
and timing of clinical results for HB-101 and other programs, and
other matters that could affect the sufficiency of existing cash to
fund operations and HOOKIPA’s ability to achieve the milestones
under the agreement with Gilead. HOOKIPA undertakes no obligation
to update or revise any forward-looking statements. For a further
description of the risks and uncertainties that could cause actual
results to differ from those expressed in these forward-looking
statements, as well as risks relating to the business of the
company in general, see HOOKIPA’s quarterly report on Form 10-Q for
the quarter ended March 31, 2020 which is available on the Security
and Exchange Commission’s website at www.sec.gov and HOOKIPA’s
website at www.hookipapharma.com.
Investors and others should note that we
announce material financial information to our investors using our
investor relations website (https://ir.hookipapharma.com/), SEC
filings, press releases, public conference calls and webcasts. We
use these channels, as well as social media, to communicate with
our members and the public about our company, our services and
other issues. It is possible that the information we post on social
media could be deemed to be material information. Therefore, we
encourage investors, the media, and others interested in our
company to review the information we post on the U.S. social media
channels listed on our investor relations website.
For further information, please contact:
Media
Nina Waibel
Senior Director - Communications
nina.waibel@hookipapharma.com
Media enquiries Instinctif Partners
hookipa@instinctif.com +44 (0)20 7457 2020
InvestorsMatt BeckExecutive Director - Investor
Relationsmatthew.beck@hookipapharma.com
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2024 to May 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From May 2023 to May 2024